For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

Member Resources

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

Image of medicine in pharmacy

Latest 340B Content

Headline
The Centers for Medicare & Medicaid Services has released a fact sheet and FAQs on the 340B Part D claims data repository that will go live Oct. 1.
Headline
The AHA Aug. 26 urged the Centers for Medicare & Medicaid Services not to finalize two proposals in the calendar year 2027 outpatient prospective payment system proposed rule, warning that the policies suffer from “serious legal defects and substantial policy shortcomings” and would place additional financial strain on hospitals and the patients and communities they serve.
340B Advocacy Alliance Bulletin
The AHA Aug. 26 urged the Centers for Medicare & Medicaid Services not to finalize two proposals in the calendar year 2027 outpatient prospective payment system proposed rule,
Letters/Comments
AHA comments on two aspects of the Centers for Medicare & Medicaid Services’ (CMS) 2027 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Rule.
Headline
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act), a legislative discussion draft that would make significant changes to the current structure and scope of the 340B program.
Letters/Comments
AHA provides feedback on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act) discussion draft.
340B Advocacy Alliance Bulletin
The AHA today submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act).
340B Advocacy Alliance Bulletin
Reminder: Submit comments on calendar year 2027 outpatient prospective payment system proposed rule by Aug. 31.
Letters/Comments
The AHA's principal recommendation is that CMS use its authority to require drug manufacturers to make the Maximum Fair Price (MFP) available through a prospective, point-of-sale mechanism and eliminate any option that would permit manufacturers to satisfy their obligations through retrospective rebates or post-sale reconciliations.
340B Advocacy Alliance Bulletin
The AHA Aug. 12 at 3 p.m. ET will host a call for 340B hospitals to discuss several aspects of the 340B Drug Pricing Program, including the rebate model and congressional activities.